% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Miederer:287258,
      author       = {M. Miederer and M. Benešová-Schäfer$^*$ and C. Mamat and
                      D. Kästner and M. Pretze and E. Michler and C. Brogsitter
                      and J. Kotzerke and K. Kopka$^*$ and D. A. Scheinberg and M.
                      R. McDevitt},
      title        = {{A}lpha-{E}mitting {R}adionuclides: {C}urrent {S}tatus and
                      {F}uture {P}erspectives.},
      journal      = {Pharmaceuticals},
      volume       = {17},
      number       = {1},
      issn         = {1424-8247},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2024-00190},
      pages        = {76},
      year         = {2024},
      abstract     = {The use of radionuclides for targeted endoradiotherapy is a
                      rapidly growing field in oncology. In particular, the focus
                      on the biological effects of different radiation qualities
                      is an important factor in understanding and implementing new
                      therapies. Together with the combined approach of imaging
                      and therapy, therapeutic nuclear medicine has recently made
                      great progress. A particular area of research is the use of
                      alpha-emitting radionuclides, which have unique physical
                      properties associated with outstanding advantages, e.g., for
                      single tumor cell targeting. Here, recent results and open
                      questions regarding the production of alpha-emitting
                      isotopes as well as their chemical combination with carrier
                      molecules and clinical experience from compassionate use
                      reports and clinical trials are discussed.},
      subtyp        = {Review Article},
      keywords     = {actinium-225 (Other) / alpha emitter (Other) / high let
                      (Other) / targeted alpha therapy (Other) / theranostic
                      (Other)},
      cin          = {E270 / DD01},
      ddc          = {610},
      cid          = {I:(DE-He78)E270-20160331 / I:(DE-He78)DD01-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38256909},
      doi          = {10.3390/ph17010076},
      url          = {https://inrepo02.dkfz.de/record/287258},
}